Related Experiment Video

Updated: Feb 26, 2026

In Silico Identification and Characterization of circRNAs During Host-Pathogen Interactions
10:27

In Silico Identification and Characterization of circRNAs During Host-Pathogen Interactions

Published on: October 21, 2022

2.0K

Circular RNAs: Unlocking new avenues in cardiometabolic disease management

Kimberley M Mellor1, Thomas D Donelly2, Gerald L M Naepi1

  • 1Department of Physiology, University of Auckland, Auckland, New Zealand.

The Journal of Physiology
|February 24, 2026
PubMed

Insights

Circular RNAs (circRNAs) show promise for treating cardiometabolic diseases by regulating gene expression. Research is exploring their potential as biomarkers and therapeutic targets despite ongoing challenges.

Area of Science:

  • Molecular Biology
  • Cardiovascular Science
  • Metabolic Science

Background:

  • Cardiometabolic diseases are a major global health issue, linked by risk factors like obesity and insulin resistance.
  • Conditions include hypertension, diabetes, heart failure, coronary artery disease, and stroke.
  • Circular RNAs (circRNAs) are key regulators of gene expression and cellular processes.

Purpose of the Study:

  • To review the potential of circRNAs as therapeutic targets for cardiometabolic diseases.
  • To explore circRNA mechanisms in disease progression, diagnostic utility, and therapeutic strategies.
  • To address challenges in circRNA research and development.

Main Methods:

  • Literature review of molecular biology and cardiometabolic disease research.
  • Analysis of circRNA functions as microRNA sponges in metabolic and cardiovascular pathways.
  • Examination of diagnostic and prognostic biomarker potential of circRNAs.

Main Results:

  • CircRNAs play a significant role in modulating key metabolic and cardiovascular pathways.
  • CircRNAs demonstrate potential as biomarkers for early diagnosis and prognosis.
  • Innovative therapeutic strategies targeting circRNAs are under development.

Conclusions:

  • CircRNAs offer emerging therapeutic potential for cardiometabolic diseases.
  • Despite research challenges, circRNAs are driving advancements in diagnostics and treatments.
  • Harnessing circRNA functions may lead to improved management of cardiometabolic conditions.

Keywords:
cardiometabolic diseasecircRNAsheart failurenon‐coding RNAstherapeutic targets

More Related Videos

Identification of Circular RNAs using RNA Sequencing08:25

Identification of Circular RNAs using RNA Sequencing

Published on: November 14, 2019

12.8K

Related Concept Videos

Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
648
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
482
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.3K
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
419
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
520
Rheumatic Heart Disease IV: Nursing Management01:20

Rheumatic Heart Disease IV: Nursing Management

AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...
370